Alex Pasteur

Alex Pasteur is currently the Director at Owkin. Prior to this, they were the Founding CEO at Orchard Therapeutics from December 2015 to November 2018. Orchard is a gene therapy company that develops treatments for patients with immuno-deficiencies and inherited metabolic diseases. Alex has also been a Partner at F-Prime Capital Partners and a Board Observer at Pulmocide.

Alex Pasteur earned a PhD in Chemistry from the University of Cambridge. Alex also holds a Master of Arts in Natural Sciences from the University of Cambridge.